生物制药公司CorMedix Inc.（纳斯达克股票代码：CRMD）今日盘中股价大涨12.60%，引发投资者广泛关注。此次显著上涨主要得益于公司发布的一系列积极财务消息。
CorMedix将2025财年的收入预期从此前的"至少3.75亿美元"上调至"3.9亿-4.1亿美元"，大幅超出市场预期。同时，公司公布的季度收入和净利润也好于分析师预估，进一步增强了投资者信心。公司表示，收入增长主要得益于其主打产品DefenCath的强劲销售表现。
值得注意的是，七家跟踪CorMedix的券商均给予"买入"或更高评级，其目标价中值为20美元，显示出分析师对公司未来发展前景的看好。截至上一交易日收盘，CorMedix股价今年已累计上涨38.2%。这一系列利好因素共同推动了公司股价在盘中交易中的显著上涨。此外，公司近期宣布将更名为CorMedix Therapeutics，进一步彰显其在生物制药领域的专注与发展决心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.